Stevanato Group (STVN) investor relations material

Operational excellence and market leadership

• Over 70 years, established as a leading provider of mission-critical solutions for the biopharma industry, serving 23 of the top 25 pharma companies and achieving a 13% revenue CAGR from FY19 to FY25.

• Global footprint with 13 production sites and ongoing investments to expand capacity and ensure supply security.

• Integrated offering across drug containment, delivery systems, and engineering, with a unique value proposition and competitive advantage.

• High-value solutions (HVS) now represent 46% of revenue, up from 17% in 2019, driving margin expansion.

• Strong secular tailwinds include aging populations, growth in biologics, and increased self-administration of medicines.

Financial performance and outlook

• FY25 revenue reached €1,186M, with adjusted EBITDA margin at 25.1% despite temporary inefficiencies.

• Q4 2025 revenue grew 5% year-over-year, with HVS revenue up 31% and gross profit margin increasing 120 bps to 30.9%.

• Biopharmaceutical and Diagnostic Solutions segment grew 10% in Q4 2025, while Engineering segment declined 23%.

• FY26 guidance projects revenue of €1.26B–€1.29B (6–9% growth), adjusted EBITDA of €332M–€347M, and HVS share rising to 47–48%.

• Free cash flow for FY25 was €18.4M, with 89% of CapEx tied to growth initiatives.

Strategic initiatives and growth drivers

• Multi-year investments in capacity expansion, R&D, and innovation to support sustainable organic growth.

• High-value solutions address unique needs of biologics, with GLP1-related revenue growing over 50% and representing 19–20% of total revenue.

• Attractive return profile for new facilities, with IRR over 20% and strong management alignment on ROIC targets.

• Engineering optimization plan underway to improve execution, operational KPIs, and long-term segment performance.

• Continued focus on integrated solutions, compliance with evolving regulations, and leveraging secular trends for long-term value creation.